{
  "data_version": "seed-0.6 · 2026-08-29",
  "source": "https://finance.foundation",
  "license": "CC BY 4.0",
  "entity": "company",
  "data": {
    "id": "novartis",
    "name": "Novartis",
    "legal_name": "Novartis AG",
    "ticker": "NOVN",
    "exchange": "six",
    "country": "switzerland",
    "sector": "Healthcare",
    "industry": "Pharmaceuticals",
    "market_cap_usd_bn": 230,
    "currency": "CHF",
    "website": "https://www.novartis.com",
    "founded": 1996,
    "description": "Basel-based pharmaceutical company created by the 1996 merger of Ciba-Geigy and Sandoz, now a pure-play innovative-medicines business after spinning off Alcon and Sandoz. Key franchises include cardiovascular, oncology and immunology drugs.",
    "identifiers": {
      "lei": "5493007HIVTX6SY6XD66",
      "isin": "CH0012005267",
      "figi": "BBG001SD31N7"
    }
  },
  "links": {
    "html": "https://finance.foundation/companies/novartis",
    "graph": "https://finance.foundation/api/v1/graph/companies/novartis"
  }
}